The purpose of the Protein Chemistry and Proteomics Shared Resource is to provide essential services in peptide synthesis, protein separation, electrophoresis, protein identification, mass spectrometry, differential proteomics, biomarker discovery, small molecule analysis and peptide quantification, computing informatics and in silico molecular modeling to Cancer Center members. This is accomplished by providing state-of-theart services, expertise and technologies. Services include: (1) Solid phase peptide synthesis by Fmoc orthogonal chemistry;(2) Synthesis of peptide/protein specific immunogens;(3) Protein separation by reverse phase HPLC and FPLC methods;(4) one-dimensional (1-D) and 2-dimensional (2-D) PAGE of protein mixtures including DIGE separation and analysis;(5) Edman chemical sequencing;(6) Protein identification by nanoLC-MS/MS methods;(7) Differential Proteomics / Biomarker discovery by tandem MS and targeted MS (e.g., MRM) methods;(8) Small molecule analysis by LC-MS and MRM methods;(9) Protein PTM analysis by nanoLC-FT-ICR mass spectrometry, and (10) Computational services for peptide design, de novo modeling of proteins, protein identification, and differential proteomics using iTRAQ and label-free methods. Future plans of the shared resource will include the development of Electron Transfer Dissociation (ETD) mass spectrometry for efficient mapping of protein post-translational modifications and chemical peptide ligation synthesis utilizing thioester methods for the chemical synthesis of small proteins and polypeptides. Cancer Center member use of the Shared Resource has increased by nearly 38% over this grant period, to more than 97 members in 2007. Cancer Center use represents 65% of the total services provided by the Shared Resource. The Protein Chemistry and Proteomics Shared Resource has been vital to Cancer Center members supporting a broad array of peer review funded research that has produced more than 400 publications during the current funding period.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications